Sample records for ANTAGONISTAS HEPARINA (heparin antagonists)
from WorldWideScience.org

Sample records 1 - 2 shown.



1

Resultados del primer registro chileno de angina inestable: características clínicas, perfil de riesgo y tratamiento/ Results of the first Chilean registry of unstable angina: Clinical features, risk profile and treatment

Corbalán H, Ramón; Nazzal N, Carolina; Eggers R, Germán; Bartolucci J, Jaime; Prieto D, Juan Carlos; Alcaíno I, Milton; Stockins F, Benjamín; Campos P, Pabla; Dapelo A, Alejandro
2004-02-01

Resumen en inglés Background: From January 2000 to June 2002, the first Chilean registry of unstable angina was carried out, with the participation of 15 hospitals. Aim: To report the clinical and demographic features of 600 patients with unstable angina, their risk profile and prognosis. Material and methods: The inclusion criteria for this prospective registry were a history of recent onset of chest pain ((mas) electrocardiographic changes and/or positive markers of myocardial damage. Results: Mean age of the patients was 65 years and 37% were women. Among coronary risk factors, 63% had hypertension, 27% had diabetes, 52% had dyslipidemia, 31% smoked and 21% had a family history of atherosclerosis. On admission 94% of patients had chest pain, associated to ST segment depression in 44%, negative T waves in 28% and positive markers of myocardial damage in 30%. Fifty seven percent received intravenous nitroglycerin, 47% received oral nitrates, 69% beta blockers and 15%, calcium antagonists. Antithrombotic therapy included aspirin in 96%, heparin in 74%, ticlodipine or clopidogrel in 19% and IIb/IIIa inhibitors in 12%. A coronary angiogram was performed in 52%, angioplasty in 25% and coronary bypass surgery in 13%. Hospital mortality was 2.6%. The incidence of new ischemic events was: myocardial infarction in 2.8% recurrent ischemia in 9.5% and refractory ischemia in 2%. The incidence of adverse events increased according to a higher risk profile. Conclusions: The demographic and clinical features, treatment and mortality of these patients are similar to those reported in international registries, with a low mortality rate (Rev Méd Chile 2004; 132: 135-43)

Scientific Electronic Library Online (Spanish)

2

Avances en la prevención de eventos tromboembólicos en pacientes con fibrilación auricular/ Update on the prevention of thromboembolic phenomena in atrial fibrillation

Montagna M, Rodrigo; Asenjo G, Rene; Morris C, Raimundo; Ortiz O, Mario; Cereceda B, Mauricio
2007-08-01

Resumen en inglés Atrial fibrillation is the most common sustained arrhythmia in clinical practice and is associated to thromboembolic complications. Anticoagulation with vitamin K antagonists is clearly useful to reduce the incidence of emboli, but associated with important limitations. Therefore, there is an active search for medications that are more effective and simpler to prescribe and manage. Synthetic pentasaccharides of heparin such as idraparinux for parenteral use, showed promis (mas) ing results. Direct inhibitors of thrombin were also useful for the prevention of thromboembolism. However, they were withdrawn from the market due to potentially fatal adverse reactions. Other area of investigation has been the effectiveness of the combination of antiplatelet agents such as aspirin and clopidrogel. Although this combination is attractive, results of clinical trials must be awaited to have an opinion about its real usefulness. Finally, ¡eft atrial appendage transcatheter occlusion (PLAATO) is an effective and reasonably safe method for patients with contraindications for anticoagulation or those that continue to embolize despite well prescribed anticoagulation. The long term results of this intervention must also be awaited (Rev Méd Chile 2007; 135: 1048-55)

Scientific Electronic Library Online (Spanish)